William Small1, Tamer Refaat2, Jonathan B Strauss3, Mahesh Gopalakrishnan3, Kevin P Bethke4, Ellen B Mendelson5, Judith A Wolfman5, Borko D Jovanovic6, Krystyna Kiel7. 1. Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Stritch School of Medicine Loyola University Chicago, 2160 S 1st Ave, Maguire Center, Rm. 2932, Maywood, IL 60153, USA. 2. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA; Department of Clinical Oncology, Alexandria University, Alexandria, Egypt; Northwestern Medicine Developmental Therapeutics Institute (NMDTI), Chicago, IL, USA. 3. Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA. 4. Department of Clinical Surgery-Breast Surgery, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA. 5. Department of Radiology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA. 6. Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA. 7. Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.
Abstract
OBJECTIVE: The purpose of this study was to report the treatment-induced adverse events and cosmetic and treatment outcomes of accelerated partial breast irradiation (APBI) delivered with the MammoSite radiation therapy system (RTS) in breast cancer patients undergoing breast-conserving therapy (BCT). METHODS: This is a prospective clinical trial that was approved by the institutional review board. The study included female breast cancer patients undergoing breast-conserving therapy in the form of surgery and APBI delivered with the MammoSite RTS. Patients and tumor characteristics, treatment-induced acute adverse events based on the Common Toxicity Criteria for Adverse Events (CTCAE) version 2.0, chronic AEs according to Radiation Therapy Oncology Group (RTOG) scale, treatment outcomes (including local control, disease-free survival, and overall survival), and cosmetic outcomes are reported. RESULTS: The study included 36 eligible patients treated consecutively in our institution between November 2003 and August 2009. The age range was 45-83 years. A total of 29 patients had invasive disease (median size 1.1 cm), while 7 patients had in situ disease only (median size 0.8 cm). The skin distance in most of the patients (91.7 %) was ≥1 cm; only three patients (8.3 %) had skin distance <1 cm. The median balloon diameter was 5 cm (range 4-6 cm). At a median follow-up of 42 months (range 4-65 months), local control, disease-free survival, and overall survival were 100 %. None of the patients experienced any grade 3 or 4 toxicities; 16.7 and 5.6 % of the patients had late grade 2 fibrosis and telangiectasia, respectively. At last follow-up, cosmetic outcome was rated as good or excellent in 94 % of the patients. CONCLUSION: APBI delivered with the MammoSite RTS is a feasible, tolerable, and effective treatment modality. Multicenter, randomized, controlled clinical trials with a larger number of patients are required for verification.
OBJECTIVE: The purpose of this study was to report the treatment-induced adverse events and cosmetic and treatment outcomes of accelerated partial breast irradiation (APBI) delivered with the MammoSite radiation therapy system (RTS) in breast cancerpatients undergoing breast-conserving therapy (BCT). METHODS: This is a prospective clinical trial that was approved by the institutional review board. The study included female breast cancerpatients undergoing breast-conserving therapy in the form of surgery and APBI delivered with the MammoSite RTS. Patients and tumor characteristics, treatment-induced acute adverse events based on the Common Toxicity Criteria for Adverse Events (CTCAE) version 2.0, chronic AEs according to Radiation Therapy Oncology Group (RTOG) scale, treatment outcomes (including local control, disease-free survival, and overall survival), and cosmetic outcomes are reported. RESULTS: The study included 36 eligible patients treated consecutively in our institution between November 2003 and August 2009. The age range was 45-83 years. A total of 29 patients had invasive disease (median size 1.1 cm), while 7 patients had in situ disease only (median size 0.8 cm). The skin distance in most of the patients (91.7 %) was ≥1 cm; only three patients (8.3 %) had skin distance <1 cm. The median balloon diameter was 5 cm (range 4-6 cm). At a median follow-up of 42 months (range 4-65 months), local control, disease-free survival, and overall survival were 100 %. None of the patients experienced any grade 3 or 4 toxicities; 16.7 and 5.6 % of the patients had late grade 2 fibrosis and telangiectasia, respectively. At last follow-up, cosmetic outcome was rated as good or excellent in 94 % of the patients. CONCLUSION:APBI delivered with the MammoSite RTS is a feasible, tolerable, and effective treatment modality. Multicenter, randomized, controlled clinical trials with a larger number of patients are required for verification.
Entities:
Keywords:
Accelerated partial breast irradiation; Brachytherapy; MammoSite
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Kari M Rosenkranz; Edmund Tsui; Elizabeth B McCabe; Jiang Gui; Kelly Underhill; Richard J Barth Journal: J Am Coll Surg Date: 2013-07-02 Impact factor: 6.113
Authors: A Trotti; R Byhardt; J Stetz; C Gwede; B Corn; K Fu; L Gunderson; B McCormick; M Morrisintegral; T Rich; W Shipley; W Curran Journal: Int J Radiat Oncol Biol Phys Date: 2000-04-01 Impact factor: 7.038
Authors: Jonathan C Nelson; Peter D Beitsch; Frank A Vicini; Coral A Quiet; Delia Garcia; Howard C Snider; Mark A Gittleman; Victor J Zannis; Pat W Whitworth; Richard E Fine; Angela J Keleher; Henry M Kuerer Journal: Am J Surg Date: 2009-03-06 Impact factor: 2.565
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-15 Impact factor: 7.038